CEO Mike Andriole was paid $1,312,421 in fiscal year 2023, ↓ down 21.5% from fiscal year 2022, the 1st percentile of its disclosed peer group (SEC filing 0001117480-24-000010 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,517,854 Mike Sherman total, FY2023 Former President and Chief Executive Officer — highest-paid officer; CEO Mike Andriole: $1,312,421 | 1st CEO (Mike Andriole) pay percentile vs peers | — CEO-to-median pay ratio | 82.99% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Mike Sherman | $514,695 | $0 | $183,112 | $778,511 | $0 | $0 | $41,536 | $1,517,854 |
| Former President and Chief Executive Officer | ||||||||
| Mike Andriole | 528,473 | 0 | 93,135 | 399,282 | 280,500 | 0 | 11,031 | 1,312,421 |
| President and Chief Executive Officer | ||||||||
| Allen Melemed | 488,408 | 0 | 50,708 | 215,588 | 166,059 | 0 | 11,031 | 931,794 |
| Chief Medical Officer | ||||||||
| Michael Alrutz | 432,180 | 0 | 42,257 | 179,656 | 128,574 | 0 | 11,187 | 793,854 |
| Senior Vice President, General Counsel and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Mike Sherman | $1,517,854 | $4,061,403 | — | ↓ −2,543,549 |
| Mike Andriole | 1,312,421 | 1,672,620 | — | ↓ −360,199 |
| Allen Melemed | 931,794 | 1,472,116 | — | ↓ −540,322 |
| Michael Alrutz | 793,854 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Chimerix's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CMRX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name CMRX as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2023 total |
|---|---|---|
| Catherine L. Gilliss | Former director (through FY2023) | $104,522 |
| Fred A. Middleton | Independent Director | $119,522 |
| Lisa L. Decker | Independent Director | $67,778 |
| Marc D. Kozin | Independent Director | — |
| Martha J. Demski | Lead Independent Director | $144,522 |
| Patrick Machado | Independent Director | $124,522 |
| Pratik S. Multani | Independent Director | $104,522 |
| Robert J. Meyer | Independent Director | $117,022 |
| Vicki Vakiener | Independent Director | $107,022 |
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Mike Andriole | Director | 2025-01-07 | A | 900,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Mike Andriole | Director | 2025-01-07 | A | 150,000 | 0 | 0 | RSU | Form 4 ↗ |
| Michael Alrutz | SVP AND GENERAL COUNSEL | 2025-01-07 | A | 250,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Alrutz | SVP AND GENERAL COUNSEL | 2025-01-07 | A | 41,667 | 0 | 0 | RSU | Form 4 ↗ |
| Thomas J. Riga | COO and CCO | 2025-01-07 | A | 325,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-01-07 | A | 41,667 | 0 | 0 | RSU | Form 4 ↗ |
| Thomas J. Riga | COO and CCO | 2025-01-07 | A | 54,275 | 0 | 0 | RSU | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-01-07 | A | 65,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-01-07 | A | 10,855 | 0 | 0 | RSU | Form 4 ↗ |
| Allen Melemed | CHIEF MEDICAL OFFICER | 2025-01-07 | A | 275,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-01-07 | A | 250,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Allen Melemed | CHIEF MEDICAL OFFICER | 2025-01-07 | A | 45,925 | 0 | 0 | RSU | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-01-30 | D | 2,800 | 4 | 11,470 | Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-01-30 | D | 1,015 | 4 | 4,172 | Common | Form 4 ↗ |
| Mike Andriole | Director | 2025-01-30 | D | 2,350 | 4 | 9,636 | Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-02-13 | D | 2,260 | 5 | 10,196 | Common | Form 4 ↗ |
| Michael Alrutz | SVP AND GENERAL COUNSEL | 2025-02-13 | D | 1,600 | 5 | 7,226 | Common | Form 4 ↗ |
| Mike Andriole | Director | 2025-02-13 | D | 7,370 | 5 | 33,282 | Common | Form 4 ↗ |
| Allen Melemed | CHIEF MEDICAL OFFICER | 2025-02-13 | D | 3,065 | 5 | 13,799 | Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-02-13 | D | 300 | 5 | 1,360 | Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 9,360 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert J. Meyer | Director | 2025-04-21 | D | 35,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Pratik S. Multani | Director | 2025-04-21 | D | 35,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Alrutz | SVP AND GENERAL COUNSEL | 2025-04-21 | D | 250,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Alrutz | SVP AND GENERAL COUNSEL | 2025-04-21 | D | 176,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Alrutz | SVP AND GENERAL COUNSEL | 2025-04-21 | D | 45,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Alrutz | SVP AND GENERAL COUNSEL | 2025-04-21 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mike Andriole | Director | 2025-04-21 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mike Andriole | Director | 2025-04-21 | D | 192,825 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mike Andriole | Director | 2025-04-21 | D | 250,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lisa L. Decker | Director | 2025-04-21 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lisa L. Decker | Director | 2025-04-21 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martha J. Demski | Director | 2025-04-21 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martha J. Demski | Director | 2025-04-21 | D | 35,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martha J. Demski | Director | 2025-04-21 | D | 21,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martha J. Demski | Director | 2025-04-21 | D | 9,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martha J. Demski | Director | 2025-04-21 | D | 9,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martha J. Demski | Director | 2025-04-21 | D | 72,055 | 9 | 616,070 | Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 65,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 18,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 29,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 28,320 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 10,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-04-21 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-04-21 | D | 64,275 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-04-21 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-04-21 | D | 62,067 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-04-21 | D | 8,098 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-04-21 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-04-21 | D | 1,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-04-21 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-04-21 | D | 181,541 | 9 | 1,552,176 | Common | Form 4 ↗ |
| Allen Melemed | CHIEF MEDICAL OFFICER | 2025-04-21 | D | 275,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allen Melemed | CHIEF MEDICAL OFFICER | 2025-04-21 | D | 240,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allen Melemed | CHIEF MEDICAL OFFICER | 2025-04-21 | D | 173,852 | 9 | 1,486,435 | Common | Form 4 ↗ |
| Robert J. Meyer | Director | 2025-04-21 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert J. Meyer | Director | 2025-04-21 | D | 35,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert J. Meyer | Director | 2025-04-21 | D | 21,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fred A. Middleton | Director | 2025-04-21 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fred A. Middleton | Director | 2025-04-21 | D | 21,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fred A. Middleton | Director | 2025-04-21 | D | 42,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fred A. Middleton | Director | 2025-04-21 | D | 531,861 | 9 | 4,547,412 | Common, indirect | Form 4 ↗ |
| Fred A. Middleton | Director | 2025-04-21 | D | 2,776,093 | 9 | 23,735,595 | Common, indirect | Form 4 ↗ |
| Fred A. Middleton | Director | 2025-04-21 | D | 60,000 | 9 | 513,000 | Common | Form 4 ↗ |
| Fred A. Middleton | Director | 2025-04-21 | D | 40,000 | 9 | 342,000 | Common | Form 4 ↗ |
| Pratik S. Multani | Director | 2025-04-21 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Pratik S. Multani | Director | 2025-04-21 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Pratik S. Multani | Director | 2025-04-21 | D | 35,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Riga | COO and CCO | 2025-04-21 | D | 800,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Riga | COO and CCO | 2025-04-21 | D | 60,828 | 9 | 520,079 | Common | Form 4 ↗ |
| Mike Sherman | Director | 2025-04-21 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mike Sherman | Director | 2025-04-21 | D | 557,050 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mike Sherman | Director | 2025-04-21 | D | 700,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mike Sherman | Director | 2025-04-21 | D | 632,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mike Sherman | Director | 2025-04-21 | D | 1,150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mike Sherman | Director | 2025-04-21 | D | 233,413 | 9 | 1,995,681 | Common | Form 4 ↗ |
| Mike Sherman | Director | 2025-04-21 | D | 102,995 | 9 | 880,607 | Common | Form 4 ↗ |
| Vicki Vakiener | Director | 2025-04-21 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Vicki Vakiener | Director | 2025-04-21 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 1,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 10,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Alrutz | SVP AND GENERAL COUNSEL | 2025-04-21 | D | 131,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Alrutz | SVP AND GENERAL COUNSEL | 2025-04-21 | D | 170,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Alrutz | SVP AND GENERAL COUNSEL | 2025-04-21 | D | 135,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mike Andriole | Director | 2025-04-21 | D | 502,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martha J. Demski | Director | 2025-04-21 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 24,950 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 156,209 | 9 | 1,335,587 | Common | Form 4 ↗ |
| Marc D. Kozin | Director | 2025-04-21 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allen Melemed | CHIEF MEDICAL OFFICER | 2025-04-21 | D | 168,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fred A. Middleton | Director | 2025-04-21 | D | 35,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fred A. Middleton | Director | 2025-04-21 | D | 207,523 | 9 | 1,774,322 | Common | Form 4 ↗ |
| Vicki Vakiener | Director | 2025-04-21 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Vicki Vakiener | Director | 2025-04-21 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Vicki Vakiener | Director | 2025-04-21 | D | 35,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Alrutz | SVP AND GENERAL COUNSEL | 2025-04-21 | D | 128,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Alrutz | SVP AND GENERAL COUNSEL | 2025-04-21 | D | 200,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martha J. Demski | Director | 2025-04-21 | D | 21,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 64,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 10,150 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-04-21 | D | 17,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-04-21 | D | 48,438 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-04-21 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert J. Meyer | Director | 2025-04-21 | D | 42,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Riga | COO and CCO | 2025-04-21 | D | 325,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mike Sherman | Director | 2025-04-21 | D | 875,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mike Sherman | Director | 2025-04-21 | D | 87,000 | 9 | 743,850 | Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mike Andriole | Director | 2025-04-21 | D | 900,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mike Andriole | Director | 2025-04-21 | D | 300,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mike Andriole | Director | 2025-04-21 | D | 450,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-04-21 | D | 250,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-04-21 | D | 95,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michelle LaSpaluto | CHIEF FINANCIAL OFFICER | 2025-04-21 | D | 18,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert J. Meyer | Director | 2025-04-21 | D | 35,150 | 9 | 300,533 | Common | Form 4 ↗ |
| Pratik S. Multani | Director | 2025-04-21 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Alrutz | SVP AND GENERAL COUNSEL | 2025-04-21 | D | 165,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Alrutz | SVP AND GENERAL COUNSEL | 2025-04-21 | D | 216,689 | 9 | 1,852,691 | Common | Form 4 ↗ |
| Mike Andriole | Director | 2025-04-21 | D | 630,828 | 9 | 5,393,579 | Common | Form 4 ↗ |
| David Jakeman | VP OF FINANCE AND ACCOUNTING | 2025-04-21 | D | 7,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mike Andriole | Director | 2025-04-21 | D | 192,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert J. Meyer | Director | 2025-04-21 | D | 21,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Pratik S. Multani | Director | 2025-04-21 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allen Melemed | CHIEF MEDICAL OFFICER | 2025-04-21 | D | 154,260 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allen Melemed | CHIEF MEDICAL OFFICER | 2025-04-21 | D | 190,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allen Melemed | CHIEF MEDICAL OFFICER | 2025-04-21 | D | 400,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert J. Meyer | Director | 2025-04-21 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fred A. Middleton | Director | 2025-04-21 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fred A. Middleton | Director | 2025-04-21 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fred A. Middleton | Director | 2025-04-21 | D | 35,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fred A. Middleton | Director | 2025-04-21 | D | 21,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Marc D. Kozin | Director | 2025-04-21 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martha J. Demski | Director | 2025-04-21 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martha J. Demski | Director | 2025-04-21 | D | 21,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert J. Meyer | Director | 2025-04-21 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Alrutz | SVP AND GENERAL COUNSEL | 2025-04-21 | D | 178,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martha J. Demski | Director | 2025-04-21 | D | 35,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| On Aug | Options/SARs | — | — | — | 150,000 | — | $25,000 |
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Mike Andriole | RSU | 25,000 | — | $24,063 |
| Allen Melemed | Option | 118,909 | 1.97 | — |
| Mike Sherman | RSU | 92,950 | — | 89,464 |
| Mike Andriole | Option | 4,011 | 2.08 | — |
| Michael Alrutz | Option | 99,091 | 1.97 | — |
| Mike Andriole | RSU | 32,175 | — | 30,968 |
| Allen Melemed | RSU | 25,740 | — | 24,775 |
| Michael Alrutz | Option | 46,042 | 9.28 | — |
| Michael Alrutz | RSU | 21,450 | — | 20,646 |
| Mike Andriole | Option | 67,708 | 9.28 | — |
| Mike Andriole | Option | 156,250 | 5.62 | — |
| Mike Andriole | Option | 148,636 | 1.97 | — |
| Mike Andriole | Option | 150,000 | 1.19 | — |
| Allen Melemed | Option | 50,000 | 3.11 | — |
| Allen Melemed | Option | 51,459 | 9.28 | — |
| Allen Melemed | Option | 125,000 | 5.62 | — |
| Michael Alrutz | Option | 3,438 | 2.08 | — |
| Michael Alrutz | Option | 104,167 | 5.62 | — |
| Mike Sherman | Option | 13,179 | 2.08 | — |
| Mike Sherman | Option | 189,584 | 9.28 | — |
| Mike Sherman | Option | 455,730 | 5.62 | — |
| Mike Sherman | Option | 429,393 | 1.97 | — |
The executive compensation program is structured to provide a competitive level of base cash compensation, with the opportunity to earn meaningfully more only upon successful performance. This structure motivates executives to achieve results for the business and value for stockholders over the long-term by tying bonuses to defined business objectives and equity awards to stock price appreciation over a multi-year period.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-20 | 37,473,111 | 7,681,297 | 174,816 | 82.99% | Passed |
| 2023 | 2023-06-09 | 36,914,776 | 10,390,731 | 2,538,527 | 78.03% | Passed |
| 2022 | 2022-06-23 | 32,981,130 | 20,478,975 | 74,913 | 61.69% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2024 | 2024-06-20 | 82.99%a |
| 2023 | 2023-06-09 | 78.03%b |
| 2022 | 2022-06-23 | 61.69%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Martha J. DemskiIndependent · Lead Independent Director · Audit | $85,000 | $0 | $59,522 | — | $0 | $144,522 |
| Patrick MachadoIndependent · Audit · Compensation (Chair) · Not standing for re-election | 65,000 | 0 | 59,522 | — | 0 | 124,522 |
| Fred A. MiddletonIndependent · Audit (Chair) | 60,000 | 0 | 59,522 | — | 0 | 119,522 |
| Robert J. MeyerIndependent · Compensation · Nominating and Governance (Chair) | 57,500 | 0 | 59,522 | — | 0 | 117,022 |
| Vicki VakienerIndependent · Compensation | 47,500 | 0 | 59,522 | — | 0 | 107,022 |
| Pratik S. MultaniIndependent · Nominating and Governance | 45,000 | 0 | 59,522 | — | 0 | 104,522 |
| Catherine L. GillissIndependent · Nominating and Governance · Not standing for re-election · Departed during FY | 45,000 | 0 | 59,522 | — | 0 | 104,522 |
| Lisa L. DeckerIndependent · Newly elected | 0 | 0 | 67,778 | — | 0 | 67,778 |
| Marc D. KozinIndependent · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Mike AndrioleEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Mike ShermanIndependent · Board Chair | — | — | — | — | 0 | — |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $405,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $405,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Chimerix names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Chimerix.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Ardelyx | 2025 | Michael Raab | $797,000 | $2,953,724 | $3,413,948 | $627,638 | $7,796,171 |
| 2 | CytomX Therapeutics | 2025 | Sean McCarthy | 675,290 | 1,150,463 | 2,158,170 | 749,572 | 4,738,495 |
| 3 | Y-mAbs Therapeutics | 2024 | Michael Rossi | 705,600 | 1,170,732 | 2,288,662 | 392,596 | 4,557,590 |
| 4 | G1 Therapeutics | 2023 | John Bailey | 794,976 | 1,392,022 | 666,209 | 387,551 | 3,250,658 |
| 5 | ALX Oncology | 2025 | Jason Lettmann | 724,500 | 0 | 1,447,488 | 298,856 | 2,470,844 |
| 6 | Precision BioSciences | 2025 | Michael Amoroso | 650,875 | 1,025,086 | 0 | 0 | 2,189,467 |
| 7 | Seres Therapeutics | 2025 | Eric Shaff | 408,333 | 0 | 1,338,870 | 0 | 1,775,549 |
| 8 | Arcturus Therapeutics | 2025 | Joseph Payne | 750,000 | 0 | 941,000 | 0 | 1,691,000 |
| 9 | Curis | 2025 | James Dentzer | 672,200 | 0 | 736,169 | 218,196 | 1,659,756 |
| 10 | Chimerix | 2023 | Mike Andriole | 528,473 | 93,135 | 399,282 | 280,500 | 1,312,421 |
| — | BioXcel Therapeutics | — | — | — | — | — | — | not in coverage universe |
| — | CymaBay Therapeutics | — | — | — | — | — | — | not in coverage universe |
| — | Gritstone bio | — | — | — | — | — | — | not in coverage universe |
| — | MEI Pharma | — | — | — | — | — | — | not in coverage universe |
| — | Trevena | — | — | — | — | — | — | not in coverage universe |
| — | VBI Vaccines | — | — | — | — | — | — | not in coverage universe |
| — | Allovir | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Chimerix | 85% | Option 86 · RSU 14 | not disclosed | Aon |
| Allovir | not disclosed | Option 100 | not disclosed | Aon plc |
| ALX Oncology | not disclosed | not disclosed | not disclosed | Compensia |
| Arcturus Therapeutics | not disclosed | Options 100 | not disclosed | not disclosed |
| Ardelyx | 105% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| BioXcel Therapeutics | not disclosed | not disclosed | not disclosed | Radford, a part of Aon plc |
| Curis | not disclosed | Option 100 | not disclosed | Willis Towers Watson |
| CymaBay Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| CytomX Therapeutics | not disclosed | not disclosed | not disclosed | Aon |
| G1 Therapeutics | not disclosed | not disclosed | not disclosed | Radford, Aon’s Human Capital Solutions Practice |
| Gritstone bio | not disclosed | not disclosed | not disclosed | not disclosed |
| MEI Pharma | not disclosed | not disclosed | not disclosed | F. W. Cook |
| Precision BioSciences | 115% | RSU 100 | not disclosed | Aon |
| Seres Therapeutics | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Trevena | not disclosed | not disclosed | not disclosed | not disclosed |
| VBI Vaccines | not disclosed | not disclosed | not disclosed | not disclosed |
| Y-mAbs Therapeutics | 85.6% | not disclosed | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Mike Sherman | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Executive Compensation”. As printed: 1,517,854. Filing ↗ |
| 2 | Section 01, Mike Andriole | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Executive Compensation”. As printed: 1,312,421. Filing ↗ |
| 3 | Section 01, Allen Melemed | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Executive Compensation”. As printed: 931,794. Filing ↗ |
| 4 | Section 01, Michael Alrutz | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Executive Compensation”. As printed: 793,854. Filing ↗machine: r4 · c24 · span 474795–474802 |
| 5 | Section 03, On Aug Options/SARs | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “EXECUTIVE AND DIRECTOR COMPENSATION EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t18 · r6 · c0 · span 511586–511592 |
| 6 | Section 08, Martha J. Demski | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 144,522. Filing ↗machine: span 677143–677393 |
| 7 | Section 08, Patrick Machado | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 124,522. Filing ↗machine: span 679731–679981 |
| 8 | Section 08, Fred A. Middleton | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 119,522. Filing ↗machine: span 682117–682367 |
| 9 | Section 08, Robert J. Meyer | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 117,022. Filing ↗machine: span 680926–681176 |
| 10 | Section 08, Vicki Vakiener | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 107,022. Filing ↗machine: span 684642–684892 |
| 11 | Section 08, Pratik S. Multani | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 104,522. Filing ↗machine: span 683314–683564 |
| 12 | Section 08, Catherine L. Gilliss | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 104,522. Filing ↗machine: span 678542–678792 |
| 13 | Section 08, Lisa L. Decker | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 67,778. Filing ↗machine: span 675632–675881 |
| 14 | Section 08, Marc D. Kozin | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 15 | Section 08, Mike Andriole | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 16 | Section 08, Mike Sherman | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 17 | Section 02, Mike Andriole 2025-01-07 | Form 4 | 2025-01-10 | 0001415889-25-001219 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Mike Andriole 2025-01-07 | Form 4 | 2025-01-10 | 0001415889-25-001219 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Michael Alrutz 2025-01-07 | Form 4 | 2025-01-10 | 0001415889-25-001220 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Michael Alrutz 2025-01-07 | Form 4 | 2025-01-10 | 0001415889-25-001220 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Thomas J. Riga 2025-01-07 | Form 4 | 2025-01-10 | 0001415889-25-001221 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Michelle LaSpaluto 2025-01-07 | Form 4 | 2025-01-10 | 0001415889-25-001224 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Thomas J. Riga 2025-01-07 | Form 4 | 2025-01-10 | 0001415889-25-001221 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, David Jakeman 2025-01-07 | Form 4 | 2025-01-10 | 0001415889-25-001222 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, David Jakeman 2025-01-07 | Form 4 | 2025-01-10 | 0001415889-25-001222 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Allen Melemed 2025-01-07 | Form 4 | 2025-01-10 | 0001415889-25-001223 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Michelle LaSpaluto 2025-01-07 | Form 4 | 2025-01-10 | 0001415889-25-001224 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Allen Melemed 2025-01-07 | Form 4 | 2025-01-10 | 0001415889-25-001223 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, David Jakeman 2025-01-30 | Form 4 | 2025-01-31 | 0001415889-25-002500 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Michelle LaSpaluto 2025-01-30 | Form 4 | 2025-01-31 | 0001415889-25-002498 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Mike Andriole 2025-01-30 | Form 4 | 2025-01-31 | 0001415889-25-002496 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Michelle LaSpaluto 2025-02-13 | Form 4 | 2025-02-14 | 0001415889-25-004212 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Michael Alrutz 2025-02-13 | Form 4 | 2025-02-14 | 0001415889-25-004216 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Mike Andriole 2025-02-13 | Form 4 | 2025-02-14 | 0001415889-25-004218 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Allen Melemed 2025-02-13 | Form 4 | 2025-02-14 | 0001415889-25-004219 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, David Jakeman 2025-02-13 | Form 4 | 2025-02-14 | 0001415889-25-004213 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Robert J. Meyer 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Pratik S. Multani 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011078 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Michael Alrutz 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Michael Alrutz 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Michael Alrutz 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Michael Alrutz 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Mike Andriole 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Mike Andriole 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Mike Andriole 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Lisa L. Decker 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011068 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Lisa L. Decker 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011068 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Martha J. Demski 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Martha J. Demski 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Martha J. Demski 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Martha J. Demski 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Martha J. Demski 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Martha J. Demski 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Michelle LaSpaluto 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Michelle LaSpaluto 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Michelle LaSpaluto 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Michelle LaSpaluto 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Michelle LaSpaluto 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Michelle LaSpaluto 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Michelle LaSpaluto 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Michelle LaSpaluto 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Michelle LaSpaluto 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Allen Melemed 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011074 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Allen Melemed 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011074 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Allen Melemed 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011074 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Robert J. Meyer 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Robert J. Meyer 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Robert J. Meyer 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Fred A. Middleton 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Fred A. Middleton 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Fred A. Middleton 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Fred A. Middleton 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Fred A. Middleton 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Fred A. Middleton 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Fred A. Middleton 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Pratik S. Multani 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011078 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Pratik S. Multani 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011078 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Pratik S. Multani 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011078 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Thomas J. Riga 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011079 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Thomas J. Riga 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011079 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Mike Sherman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Mike Sherman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Mike Sherman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Mike Sherman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Mike Sherman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Mike Sherman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Mike Sherman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Vicki Vakiener 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011082 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Vicki Vakiener 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011082 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Michael Alrutz 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Michael Alrutz 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Michael Alrutz 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Mike Andriole 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Martha J. Demski 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Marc D. Kozin 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Allen Melemed 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011074 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Fred A. Middleton 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Fred A. Middleton 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Vicki Vakiener 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011082 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Vicki Vakiener 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011082 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Vicki Vakiener 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011082 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Michael Alrutz 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Michael Alrutz 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Martha J. Demski 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Michelle LaSpaluto 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Michelle LaSpaluto 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Michelle LaSpaluto 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Robert J. Meyer 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Thomas J. Riga 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011079 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Mike Sherman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Mike Sherman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Mike Andriole 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Mike Andriole 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Mike Andriole 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Michelle LaSpaluto 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Michelle LaSpaluto 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Michelle LaSpaluto 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Robert J. Meyer 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Pratik S. Multani 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011078 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Michael Alrutz 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Michael Alrutz 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Mike Andriole 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, David Jakeman 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Mike Andriole 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Robert J. Meyer 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Pratik S. Multani 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011078 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Allen Melemed 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011074 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Allen Melemed 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011074 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Allen Melemed 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011074 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Robert J. Meyer 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Fred A. Middleton 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Fred A. Middleton 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Fred A. Middleton 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Fred A. Middleton 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Marc D. Kozin 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Martha J. Demski 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Martha J. Demski 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Robert J. Meyer 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Michael Alrutz 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Martha J. Demski 2025-04-21 | Form 4 | 2025-04-21 | 0001415889-25-011069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 06, 2024 vote | Form 8-K | 2024-06-21 | 0001104659-24-073907 | Item 5.07 · say-on-pay result. As reported: 82.99% (votes for as printed: 37,473,111). Filing ↗ |
| 157 | Section 06, 2023 vote | Form 8-K | 2023-06-12 | 0001104659-23-070155 | Item 5.07 · say-on-pay result. As reported: 78.03% (votes for as printed: 36,914,776). Filing ↗ |
| 158 | Section 06, 2022 vote | Form 8-K | 2022-06-28 | 0001117480-22-000027 | Item 5.07 · say-on-pay result. As reported: 61.69% (votes for as printed: 32,981,130). Filing ↗ |
| 159 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 160 | Section 09b board cost (computed) | Computed | — | — | Cash 405,000 + equity 0 + all other 0 = 405,000, summed across the director compensation table rows.machine: formula: Σ = 405,000 |
| 161 | Ardelyx, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001140361-26-017800 | CEO total compensation as printed in Ardelyx's own proxy. As printed: 7,796,171. Filing ↗machine: r2 · c25 · span 677112–677121 |
| 162 | CytomX Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001140361-26-018237 | CEO total compensation as printed in CytomX Therapeutics's own proxy. As printed: 4,738,495. Filing ↗machine: r2 · c24 · span 739353–739362 |
| 163 | Y-mAbs Therapeutics, Section 10b CEO total | DEF 14A | 2025-05-30 | 0001558370-25-008299 | CEO total compensation as printed in Y-mAbs Therapeutics's own proxy. As printed: 4,557,590. Filing ↗machine: r5 · c23 · span 597595–597604 |
| 164 | G1 Therapeutics, Section 10b CEO total | DEF 14A | 2024-04-25 | 0001193125-24-113902 | CEO total compensation as printed in G1 Therapeutics's own proxy. As printed: 3,250,658. Filing ↗machine: r3 · c31 · span 348805–348814 |
| 165 | ALX Oncology, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001193125-26-163936 | CEO total compensation as printed in ALX Oncology's own proxy. As printed: 2,470,844. Filing ↗machine: r2 · c29 · span 706901–706910 |
| 166 | Precision BioSciences, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001140361-26-013757 | CEO total compensation as printed in Precision BioSciences's own proxy. As printed: 2,189,467. Filing ↗machine: r2 · c19 · span 829996–830005 |
| 167 | Seres Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182036 | CEO total compensation as printed in Seres Therapeutics's own proxy. As printed: 1,775,549. Filing ↗machine: r2 · c29 · span 928055–928064 |
| 168 | Arcturus Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193805-26-000507 | CEO total compensation as printed in Arcturus Therapeutics's own proxy. As printed: 1,691,000. Filing ↗machine: t116 · r1 · c27 · span 296910–296919 |
| 169 | Curis, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001108205-26-000053 | CEO total compensation as printed in Curis's own proxy. As printed: 1,659,756. Filing ↗ |
| 170 | Chimerix (subject), Section 10b CEO total | DEF 14A | 2024-04-26 | 0001117480-24-000010 | CEO total compensation as printed in Chimerix's own proxy. As printed: 1,312,421. Filing ↗ |
| 171 | Section 10a, Arcturus Therapeutics reciprocity | DEF 14A | — | 0001193805-26-000507 | Arcturus Therapeutics's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗ |
| 172 | Section 10a, Ardelyx reciprocity | DEF 14A | — | 0001140361-26-017800 | Ardelyx's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗ |
| 173 | Section 10a, G1 Therapeutics reciprocity | DEF 14A | — | 0001193125-24-113902 | G1 Therapeutics's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗ |
| 174 | Section 10a, Seres Therapeutics reciprocity | DEF 14A | — | 0001193125-26-182036 | Seres Therapeutics's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗ |
| 175 | Section 10a, Y-mAbs Therapeutics reciprocity | DEF 14A | — | 0001558370-25-008299 | Y-mAbs Therapeutics's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗ |
| 176 | Section 10a, Precision BioSciences reciprocity | DEF 14A | — | 0001140361-26-013757 | Precision BioSciences's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.